Viewing Study NCT05244993


Ignite Creation Date: 2025-12-25 @ 12:59 AM
Ignite Modification Date: 2025-12-25 @ 11:13 PM
Study NCT ID: NCT05244993
Status: UNKNOWN
Last Update Posted: 2022-07-12
First Post: 2022-02-08
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer
Sponsor: Liaoning Cancer Hospital & Institute
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module